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155Deﬁning utility and predicting outcome of
cadaveric lower extremity bypass grafts in patients
with critical limb ischemia
Catherine K. Chang, MD, Salvatore T. Scali, MD, Robert J. Feezor, MD, AdamW. Beck, MD,
AlysonL.Waterman,MD,MPH,Thomas S.Huber,MD,PhD, andScottA.Berceli,MD,PhD,Gainesville, Fla
Objective: Despite poor long-term patency, acceptable limb salvage has been reported with cryopreserved saphenous vein
bypass (CVB) for various indications. However, utility of CVB in patients with critical limb ischemia (CLI) remains
undeﬁned. The purpose of this analysis was to determine the role of CVB in CLI patients and to identify predictors of
successful outcomes.
Methods: A retrospective review of all lower extremity bypass (LEB) procedures at a single institution was completed, and
CVB in CLI patients were further analyzed. The primary end point was amputation-free survival. Secondary end points
included primary patency and limb salvage. Life tables were used to estimate occurrence of end points. Cox regression
analysis was used to determine predictors of limb salvage.
Results: From 2000 to 2012, 1059 patients underwent LEB for various indications, of whom 81 received CVB for either
ischemic rest pain or tissue loss. Mean age (6standard deviation) was 66 6 10 years (male, 51%; diabetes, 51%; hemo-
dialysis dependence, 12%), and 73% (n[ 59) had history of failed ipsilateral LEB or endovascular intervention. None had
sufﬁcient autogenous conduit for even composite vein bypass. Infrainguinal CVB (infrapopliteal target, 96%; n[ 78) was
completed for multiple indications including Rutherford class 4 (42%; n[ 34), class 5 (40%; n[ 32), and class 6 (18%;
n [ 15). Eleven (14%) had CLI and concomitant graft infection (n [ 8) or acute on chronic ischemia (n [ 3). Intra-
operative adjuncts (eg, profundaplasty, suprainguinal stent or bypass) were completed in 49% (n [ 40) of cases. Com-
plications occurred in 36% (n[ 29), with 30-day mortality of 4% (n [ 3). Median follow-up for CLI patients was 11.8
(interquartile range, 0.4-28.4) months with corresponding 1- and 3-year actuarial estimated survival (6standard error
mean) of 84% 6 4% and 62% 6 6%. Primary patency of CVB for CLI was 27% 6 6% and 17% 6 6% at 1 and 3 years,
respectively. Amputation-free survival was 43% 6 6% and 23%6 6% at 1 and 3 years, respectively, and signiﬁcantly higher
for rest pain (59%6 9%, 36%6 10%) compared with tissue loss (31%6 7%, 14%6 7%; log-rank, P[ .04). Freedom from
major amputation after CVB for CLI was 57% 6 6% and 43% 6 7% at 1 and 3 years. Multivariable predictors of limb
salvage for the CVB CLI cohort included postoperative warfarin (hazard ratio [HR], 0.4; 95% conﬁdence interval [CI],
0.2-0.8), dyslipidemia (HR, 0.4; 95% CI, 0.2-0.9), and rest pain (HR, 0.4; 95% CI, 0.2-0.9). Predictors of major
amputation included graft infection (HR, 3.1; 95% CI, 1.1-9.0).
Conclusions: In CLI patients with no autologous conduit and prior failed infrainguinal bypass, CVB outcomes are
disappointing. CVB performs best in patients with rest pain, particularly those who can be anticoagulated with warfarin.
However, it may be an acceptable option in patients with minor tissue loss or concurrent graft infection, but consider-
ation should be weighed against the known natural history of nonrevascularized CLI and nonbiologic conduit alterna-
tives, given potential cost implications. (J Vasc Surg 2014;60:1554-64.)the Division of Vascular Surgery and Endovascular Therapy, University
Florida.
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4The most important determinate of lower extremity
bypass (LEB) outcomes in patientswith critical limb ischemia
(CLI) is availability of autologous vein.1-3 However, up to
30% of CLI patients present with inadequate or unavailable
autogenous conduit.4-6 In this scenario, a variety of alterna-
tive conduit choices exist, including prosthetic and nonau-
togenous biologic grafts. In 1955, Linton described the
ﬁrst clinical use of a homologous saphenous vein allograft,7
and reports in the 1970s highlighted the utility of cryopre-
served saphenous vein bypass (CVB) for infrainguinal arterial
reconstruction.8 Since that time, cryopreserved allografts
have been implanted for numerous indications, the most
common being limb-threatening ischemia and infection.9-11
Several series have documented dismal 1-year primary
patency (w25%-30%) of CVB in CLI patients, tempering
enthusiasm for these conduits because prosthetic grafts
have similar or better outcomes at relatively reduced
Table I. Demographics and comorbidities
Characteristic
All (N ¼ 112),
No. (%)
CLI (n ¼ 81),
No. (%)
Age, years, mean 6 SD 66 6 10 66 6 10
Male 60 (54) 41 (51)
Body mass index, kg/m2,
mean 6 SD
26 6 6 25 6 5
Comorbidities
Hypertension 106 (95) 77 (95)
Tobacco use (past
or current)
81 (72) 56 (69)
Coronary artery disease 68 (61) 51 (63)
Dyslipidemia 77 (69) 47 (71)
Diabetes 53 (47) 41 (51)
Chronic obstructive
pulmonary disease
31 (28) 26 (32)
Congestive heart failure 29 (26) 22 (27)
Cerebrovascular occlusive
disease
25 (22) 18 (22)
Renal insufﬁciency
(eGFR <50)
29 (26) 25 (31)
Dialysis dependent 10 (9) 10 (12)
Preoperative medications
Aspirin 97 (87) 73 (90)
Clopidogrel 24 (22) 19 (23)
Statin 62 (56) 47 (58)
Warfarin 28 (25) 22 (27)
CLI, Critical limb ischemia; eGFR, estimated glomerular ﬁltration rate;
SD, standard deviation.
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rates (42%-78%) for CVB in CLI have been reported, sug-
gesting that these grafts are worthy of consideration in
selected patients.13 Moreover, patients with overt lower
extremity infection and no usable autogenous conduit
may be a speciﬁc subpopulation in which CVB offers an
advantage over prosthetic conduits, given their relative
resistance to infection.11 In addition, few studies charac-
terize CVB outcomes in the context of recently proposed
objective performance goals for CLI therapies.14,15
Because of the lack of rigorous comparative effective-
ness data, the utility of CVB in CLI patients remains unde-
ﬁned. The purpose of this analysis was to determine the
role of CVB in CLI patients and to identify predictors of
successful outcomes.
METHODS
Database and subjects. This study was approved by
the Institutional Review Board at the University of Florida
(IRB #201300025). A waiver of informed consent was
granted because all collected data pre-existed in medical re-
cords and no study related interventions or subject contact
occurred. Therefore, the rights and welfare of these sub-
jects was not adversely affected. All patients who under-
went infrainguinal bypass from 2000 to 2012 for any
indication were retrospectively reviewed. Subjects receiving
cryopreserved allografts were further analyzed. Patients
receiving autogenous vein or prosthetic bypass were
excluded from analysis. Patient demographics, prior
vascular surgery history, noninvasive vascular laboratory
testing, postoperative reintervention or reoperation, minor
or major amputation, and use of statins, antiplatelets, and
anticoagulants were recorded. Comorbidities and complica-
tions were recorded and deﬁned on the basis of recommen-
ded reporting standards.16
Clinical practice. All subjects underwent preoperative
digital subtraction angiography with bilateral upper and
lower extremity vein mapping. Patients had multilevel
occlusive disease for which endovascular salvage was
deemed unfeasible by the treating surgeon. CVB was
offered to patients only if they had insufﬁcient autogenous
conduit even for composite vein bypass. Our group’s phi-
losophy on infrainguinal bypass, vein mapping assessment,
and arteriogram interpretation has been previously re-
ported.17,18 The hierarchy for conduit selection was ipsi-
lateral greater saphenous vein > contralateral saphenous
vein (if ankle-brachial index >0.6 in that limb), arm vein
>> nonautogenous biologic or prosthetic grafts. Pros-
thetic bypass with a vein cuff19 was an alternative conduit
used in a minority of subjects with inadequate autogenous
vein, primarily those with good runoff and low risk of
infection. Need for intraprocedural adjuncts, such as
concomitant suprainguinal stent or bypass, femoral recon-
struction or bypass, and distal anastomotic vein patch or
digital/forefoot amputation, was left to the operating
surgeon’s discretion.
Cadaveric saphenous vein was obtained at a cost of
$7000 to $7500 per vessel. Grafts were stored in aproprietary tissue cryoprotectant solution containing Dul-
becco’s Modiﬁed Eagle’s Medium with dimethyl sulfoxide,
fetal bovine serum, and chondroitin sulfate at or
below 135C that did not change during the study
interval (Cryograft; CryoLife, Kennesaw, Ga). Donor char-
acteristics and storage times were veriﬁed by direct commu-
nication with the manufacturer. Grafts were thawed and
prepared per instructions for use. Single-segment grafts
were preferred; however, in selected cases, composite grafts
were constructed with arterial or venous cadaveric products
if any section had poor integrity (eg, thin-walled or aneu-
rysmal sections, synechia, webs, or sclerotic segments).
Implantation technique. Grafts were dilated with a
heparin/papaverine hydrochloride solution (60 mg papav-
erine hydrochloride, 5000 units heparin, and 4C Plasma-
lyte). Early in the study interval, routine ABO/Rh blood
group matching was performed; however, evolving litera-
ture bias9,13,20 and conduit availability led to decreased
prioritization of matching over the duration of this review.
Patients were heparinized (80-100 units/kg initial bolus),
and intraprocedural activated clotting time was generally
maintained $250 seconds during reconstruction. On
completion of the distal anastomosis, adequacy of the bypass
was determined by angiography and the presence of graft-
dependent pedal pulses or Doppler signals. Selective use of
distal anastomotic adjuncts (eg, vein patch19) was based on
the surgeon’s preference, particularly for small (<2 mm) or
diseased tibial targets requiring local endarterectomy. Prot-
amine (1mg/100 units heparin) was routinely administered
to reverse the heparin effect at case completion.
Table II. Operative details and donor characteristics in
critical limb ischemia (CLI) patients
Operative details N ¼ 81, No. (%)
Bypass conﬁguration
Proximal anastomosis
External iliac artery 1 (1)
Common femoral artery 76 (94)
Superﬁcial femoral artery 3 (4)
Profunda femoris artery 1 (1)
Distal anastomosis
Above-knee popliteal artery 3 (4)
Below-knee popliteal artery 7 (9)
Tibial artery 70 (86)
Tibioperoneal trunk 2 (2)
Posterior tibial artery 28 (35)
Anterior tibial artery 21 (26)
Peroneal artery 19 (23)
Dorsalis pedis artery 1 (1)
Conduit conﬁguration
Reversed greater saphenous vein 43 (53)
Nonreversed greater saphenous vein 29 (36)
Composite saphenous vein 7 (9)
Composite vein/artery 2 (4)
Adjuncts (any) 40 (49)
Inﬂow procedure 28 (34)
Distal anastomotic adjunct 5 (6)
Donor characteristics N ¼ 73
Age, years 6 SD 38 6 13
Male 99% (72)
Preservation time, days 6 SD 196 6 143
ABO/Rh matched 41% (55)
SD, Standard deviation.
Table III. Outcomes after cadaveric vein lower
extremity bypass (LEB) in critical limb ischemia (CLI)
patients
Outcome N ¼ 81
Thirty-day mortality 3 (4)
In-hospital mortality 3 (4)
Median length of stay, days (IQR) 7 (5-11)
Any complication 29 (37)
Wound/bleeding 18 (22)
Pulmonary 6 (7)
Cardiac 5 (6)
Gastrointestinal 5 (6)
Renal 4 (5)
Neurologic 3 (4)
Genitourinary 3 (4)
Postoperative medications
Aspirin 76 (94)
Statin 57 (70)
Warfarin 50 (62)
Clopidogrel or dipyridamole 22 (27)
IQR, Interquartile range.
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treated with postoperative antiplatelet therapy (aspirin un-
less a conﬁrmed allergy existed), and as practice evolved,
patients were also increasingly prescribed statin therapy.
Anticoagulation with warfarin sodium (goal international
normalized ratio of 2-3) was initiated at the operating sur-
geon’s discretion on the basis of the assessment of the like-
lihood of graft failure, determined by distal target artery
quality and completion arteriography. No immunomodula-
tory therapy was used to augment graft patency.
Postoperative surveillance included ankle-brachial
indices performed at 1 month, then at 3-month intervals
in the ﬁrst year, and then semiannually. Most patients
also underwent duplex ultrasound examination according
to the same schedule. CVB grafts were considered at risk
for thrombosis if a 3.5 step-up in peak systolic velocity
was discovered on postoperative duplex ultrasound exami-
nation, particularly when accompanied by a 0.15 reduction
in ankle-brachial index. Type and timing of reintervention
were left to the operating surgeon’s discretion. Patency
from the date of initial operation to the date of thrombosis
was determined by graft imaging (duplex ultrasound or
arteriography) or the ﬁrst documented onset of ischemic
symptoms or reintervention. Thrombosis was veriﬁed by
duplex ultrasound if no ﬂow within the graft was detected
by clinical examination.Deﬁnitions. Minor amputations included digital and
transmetatarsal resections; major amputation was deﬁned
as above the ankle. The degree of chronic limb ischemia
was classiﬁed by the Rutherford scale.16 Objective per-
formance goals proposed by the Society for Vascular
Surgery14,21 were selectively applied to better understand
utility of CVB. Speciﬁcally, amputation-free survival
(AFS) and major adverse limb events (MALEs) were
analyzed.
To study AFS, our primary outcome was major ampu-
tation ipsilateral to the index cadaveric saphenous vein
bypass or death from any cause, whichever occurred ﬁrst.
A second ipsilateral CVB was analyzed as a MALE and
loss of patency. Contralateral CVBs were not analyzed.
Therefore, 112 ipsilateral CVB allografts in 112 patients
were included in this analysis. Each patient’s study period
began on the index CVB date and continued until the
outcome occurred or until August 1, 2013. Mortality
events were veriﬁed with the Social Security Index Master-
ﬁle. Limb salvage was the time from CVB to ipsilateral ma-
jor amputation. Primary patency was deﬁned as time from
implant free from graft thrombosis and reintervention.
MALEs were recorded if the index CVB limb underwent
major amputation or any major vascular reintervention
(thrombectomy, thrombolysis, new bypass graft, jump/
interposition graft revision).14
End points and statistics. The primary end point was
AFS. Secondary end points included primary patency, limb
salvage, and MALEs. Categorical variables were summa-
rized with frequencies and percentages. Normally distrib-
uted continuous variables were analyzed with means and
standard deviations; nonparametric data were examined
by medians with interquartile range (IQR). Comparisons
of characteristics in subgroup analysis were performed
with Fisher exact test, two-sample t-test, Wilcoxon rank
sum text, and analysis of variance, when appropriate.
Fig 1. This Kaplan-Meier curve depicts the overall survival for patients receiving cadaveric vein bypass for a critical limb
ischemia (CLI) indication. Actuarial estimated survival at 1 and 3 years is 84% (95% conﬁdence interval [CI], 74-90) and
62% (95% CI, 49-72), respectively. All displayed time intervals have <10% standard error of the mean.
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freedom from MALEs were estimated by Kaplan-Meier
life-table methodology and compared between subgroups
by the log-rank test. Cox regression was used to develop
a model to predict major amputation. Variables found on
univariate analysis to have P < .2 were included in the
multivariable model, which was reﬁned with stepwise back-
ward regression and log-likelihood ratio testing. All statisti-
cal analysis was performed with STATA 11 software
(StataCorp, College Station, Tex). A P < .05 was consid-
ered signiﬁcant.
RESULTS
Patient cohort. From 2000 to 2012, 1059 patients
underwent LEB, of whom 112 (11%) had a total of 127
CVB grafts implanted. This cohort had a mean age
(6standard deviation) of 66 6 10 years, and 54% (n ¼ 60)
were male. Notably, 47% (n ¼ 53) were diabetic and
9% (n ¼ 10) were hemodialysis dependent. Additional
details of patient demographics and comorbidities of
the entire cohort as well as of the CLI patients are
highlighted in Table I.
A majority of patients (65%; n ¼ 73) had a history
of failed ipsilateral, infrainguinal leg bypass, and 72%
(n ¼ 81) had a history of failed leg bypass or endovascular
intervention. A signiﬁcant proportion (52%) of the patients
had a preoperative American Society of Anesthesiologists
score of 4, and 37% (n ¼ 41) of the cases were performed
urgently or emergently. Among all CVB patients (n ¼ 112),
Rutherford classiﬁcation was class 3 in 3% (n ¼ 3, all with
graft infection), class 4 in 30% (n ¼ 34), class 5 in 29% (n ¼
32), class 6 in 13% (n ¼ 15), and nonapplicable in 25%
(n ¼ 28; 13 with acute ischemia, 12 with graft infection,and three with both). Of the 81 CLI patients, 11 (14%)
had concomitant graft infection (n ¼ 8) or acute on
chronic limb ischemia (n ¼ 3).
CLI patients. In focusing only on CLI patients
(n ¼ 81), mean (6standard deviation) preoperative
ankle-brachial index was 0.27 6 0.18, and median toe
brachial index was 0 (IQR, 0-0.1). Intraoperative adjuncts
were completed in 49% (n ¼ 40) of cases. Operative details
and speciﬁc donor characteristics of the various allografts
used in CLI patients are detailed in Table II (and the
Supplementary Table, for the entire cohort). Notably,
valves were lysed in 36% (n ¼ 29) of cases, and the com-
mon femoral artery was the most common site of inﬂow
(94%); an infrapopliteal target artery was used in 96% of
cases. ABO/Rh-matched grafts were implanted in 55%
(n ¼ 41) of cases, and most of the allografts came from
younger, male donors with mean preservation time of
196 6 143 days.
CLI patient outcomes. The 30-day mortality in CLI
patients was 4% (n ¼ 3), and complications occurred in
37% of cases (n ¼ 29). The most frequent complication was
wound morbidity in 22% (n ¼ 18). Table III demonstrates
the outcomes of all CLI patients undergoing CVB.Median
follow-up time for CLI patients was 11.8 (IQR, 0.4-28.4)
months, with corresponding 1- and 3-year actuarial esti-
mated survival (6standard error mean) of 84% 6 4% and
62% 6 6% (Fig 1). Primary patency of CVB for CLI was
27%6 6% and 17%6 6% at 1 and 3 years, respectively (Fig 2,
A). There were 24 patients (30%) who underwent revision
of a failing or failed CVB. The 1- and 3-year primary-assisted
patency was 39% 6 6% and 18% 6 7%, respectively (Fig 2,
B). The types of reinterventions that were performed to
remediate the CVB grafts are listed in Table IV. In the 70%
Fig 2. A, Primary patency of cadaveric vein bypass in critical limb ischemia (CLI) patients was 27% (95% conﬁdence interval
[CI], 16-39) and17% (95%CI, 7-30) at 1 and3 years, respectively.B,Theprimary-assisted patency after cadaveric vein bypass
for a CLI indication was not signiﬁcantly different from the primary patency despite that a majority of patients underwent
routine postoperative duplex ultrasound surveillance and had a reintervention threshold of a peak systolic velocity step-up of
3.5 or drop in ankle brachial index$0.15. All displayed time intervals have<10% standard error of the mean.
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surveillance after CVB, reinterventions were found to be
more frequent compared with those who did not (32% vs
15%; P ¼ .06); however, no improvement in primary-
assisted patency was noted (P ¼ 1).
A total of 47 grafts (58%) thrombosed during the
follow-up interval, and 36 CLI patients underwent major
amputation (above knee; n ¼ 31; 38%). Median time
from initial graft thrombosis to major amputation was0.6 (IQR, 0.1-3.1) months. Notably, eight of 36 patients
underwent major amputation without experiencing graft
failure. Nineteen patients experienced CVB thrombosis
and did not subsequently undergo major amputation.
The indications for this subset of patients included rest
pain (n ¼ 8), Rutherford class 5 (n ¼ 4), Rutherford class
6 (n ¼ 4), and mixed indications (n ¼ 3). Most (n ¼ 13)
did not undergo a concomitant inﬂow procedure at the
time of CVB.
Table IV. Procedures performed to remediate failing or
thrombosed cadaveric bypass in critical limb ischemia (CLI)
patients
Procedure type No.
Balloon angioplasty 6 stent for critical stenosis 6
Redo bypass 5
Open graft revision 5
Ligation 3
Thrombectomy 6 graft revision 2
Thrombolysis 1
Excision of aneurysmal degeneration 1
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respectively, and signiﬁcantly higher for rest pain (59% 6
9%, 36% 6 10%) compared with tissue loss (31% 6 7%,
14% 6 7%; log-rank, P¼ .04) (Fig 3), in contrast to primary
patency and survival, which did not differ by indication.
Freedom from major amputation after CVB for CLI was
57% 6 6% and 43% 6 7% at 1 and 3 years, respectively
(Fig 4, A), and signiﬁcantly higher for rest pain patients
compared with those with tissue loss (Fig 4, B). Freedom
from MALEs for all CLI patients was 47% 6 7% at 1 year
and 25% 6 7% at 3 years (Fig 5, A) and again higher for a
rest pain indication compared with tissue loss (Fig 5, B).
Multivariable predictors for limb salvage in CLI
patients included postoperative warfarin (hazard ratio
[HR], 0.4; 95% conﬁdence interval [CI], 0.2-0.8), dyslipi-
demia (HR, 0.4; 95% CI, 0.2-0.9), and rest pain (HR, 0.4;
95% CI, 0.2-0.9). Predictors of major amputation included
graft infection (HR, 3.1; 95% CI, 1.1-9.0).
DISCUSSION
This study analyzed the results of patients undergoing
CVB for CLI and conﬁrmed that these conduits have
poor patency. Rates of MALEs were signiﬁcant in this
cohort of patients with insufﬁcient autogenous conduit in
which a majority had a history of prior failed ipsilateral
infrainguinal revascularization. Despite the dismal patency,
acceptable AFS was observed for the subset of patients
with rest pain. Notably, in addition to an indication of rest
pain, preoperative dyslipidemia and postoperative warfarin
therapy independently predicted improved limb salvage,
whereas operations performed for graft infection predicted
the highest risk of subsequent ipsilateral major amputation.
To our knowledge, this series represents one of the ﬁrst to
report multiple patient and periprocedural factors that are
independent predictors of limb salvage after CVB, rather
than patency, as well as to apply selected objective perfor-
mance goals in an attempt to understand clinical efﬁcacy.
These data provide further insight into the utility of CVB
in CLI patients and designate which patients may derive
the most beneﬁt from this revascularization strategy.
The merits of revascularization are well established,
even in patients presenting with a failed ipsilateral LEB
and CLI.4,5,19,22 Autogenous vein is the preferred conduit
for infrainguinal reconstruction, especially because manyCLI patients have a disease pattern that is not amenable
to endovascular therapy and require crural bypass for
adequate revascularization.16,21,23 CLI patients with insuf-
ﬁcient autogenous vein require nonautogenous biologic
or synthetic conduits, which have mixed, often poor,
results.6,11,12,19,24 These outcomes have led some authors
to question whether use of such conduits is futile and to
advocate for earlier consideration of primary amputation.25
Given that reported outcomes of CVB are frequently from
high-risk CLI cohorts,8,9,11,26 the inherent selection bias
makes it challenging to determine which clinical scenarios,
if any, are best treated with this conduit.
Despite discouraging CVB graft patency, acceptable
limb salvage rates of 50% to 75% at 1 to 3 years have
been reported.9,13,26 Indeed, comparable rates were
observed in our series of Rutherford class 4 patients. His-
torically, metrics of success after LEB have focused on graft
patency, limb salvage, and death. More recently, outcomes
focusing on freedom from MALEs, AFS, and functional
outcome have been suggested as more ﬁtting criteria for
evaluating CLI therapies.21,27,28 By use of this framework,
outcomes of CVBs are sobering because 1-year freedom
from MALE and AFS in our experience was 47% and
43%, respectively.
At ﬁrst glance, these results appear dismal, although
most of these patients were likely facing major amputation.
Nearly 75% of the patients in this series presented with CLI
or history of failed prior LEB, and none had sufﬁcient
autogenous conduit even for composite arm vein bypass.
This subset of patients has a 60% to 80% risk of major
amputation at 1 year, a 20% chance of death within
6 months, and a 15% risk of contralateral amputation
within 2 years.23 The rationale for attempting infragenicu-
late revascularization in this group of high-risk patients re-
ﬂects the aggressive limb salvage philosophy within our
group. An important factor that likely formed our bias in
favor of crural bypass over primary amputation is the
notably young mean age of the patients in our series at
66 6 10 years compared with others studies.9,29,30
Several factors have been reported to inﬂuence CVB
results. Immunomodulation, ABO/Rh matching, degree
of tissue loss, and certain patient-level factors like diabetes
and renal failure have been variably linked to outcomes af-
ter CVB.9,13,26 However, most reports have focused on
understanding factors predicting CVB graft patency.
Because graft patency is not the best indicator of clinical
success,31 we chose to analyze the performance of CVB
with respect to more patient-centered outcomes. We
focused on limb salvage, as this was the goal of therapy.
Limb salvage was found to be positively affected by a pre-
operative diagnosis of dyslipidemia. The seemingly protec-
tive effect of hyperlipidemia (HR, 0.4) has been reported in
other series31 and may be a proxy for statin use or a patient
cohort with improved access to health care.
Interestingly, postoperative warfarin anticoagulation
also predicted improved limb salvage, which intuitively
can be hypothesized to augment graft patency. However,
primary patency was not signiﬁcantly improved by warfarin
Fig 3. Amputation-free survival (AFS) was signiﬁcantly different (log-rank, P ¼ .04) between patients undergoing
cadaveric vein bypass for a rest pain indication and subjects with tissue loss. All displayed time intervals have <10%
standard error of the mean.
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outcomes.9,13 Patients in our practice managed with anti-
coagulation after LEB are typically younger, have better
functional status with corresponding lower fall risk, and
have sufﬁcient compliance to adhere to anticoagulation
surveillance, which could confound these outcomes. Pre-
sentation with rest pain was also predictive of improved
AFS and could potentially be explained by two factors.
First, the natural history of rest pain with or without suc-
cessful revascularization is better than that for ischemic tis-
sue loss.23 Second, rest pain patients in this series were
more likely to undergo a concomitant inﬂow procedure
compared with tissue loss patients (50% vs 23%; P ¼ .02),
and this likely improved the eventual outcome of the
bypassed limb.
A noteworthy distinction about this analysis is the
incorporation of more donor- and procedure-speciﬁc infor-
mation compared with other CVB series.9,11,26 Donor age,
gender, ABO/Rh characteristics, and preservation time
were all evaluated but did not signiﬁcantly affect outcomes.
Distal anastomotic adjuncts, such as vein cuffs or arteriove-
nous ﬁstulas, were seldom employed because they have not
consistently been proved to improve results of cadaveric
allograft or prosthetic crural bypasses.9,13,32,33 Although
the study was not designed to determine the utility of
duplex ultrasound surveillance, it is notable that 70% of
patients had postoperative duplex imaging. Patients under-
going surveillance seemed more likely to also undergo rein-
terventions (32% vs 15%; P ¼ .06), but no improvement
in primary-assisted patency was noted between patients
evaluated with duplex ultrasound and those without sur-
veillance (P ¼ 1). Similar to polytetraﬂuoroethylene
(PTFE) grafts, routine surveillance does not appear toreliably predict impending CVB failure, unlike that for
autogenous bypasses.13,34,35 In addition, secondary proce-
dures for failing or failed CVB grafts were not common in
this series, and their success rate did not signiﬁcantly affect
AFS (P ¼ .3).
Given these marginal outcomes with CVB, logical com-
parisons for consideration are PTFE bypass, endovascular
therapy, and primary amputation in CLI patients without
autogenous vein. A meta-analysis by Albers et al36 reported
the 1- and 5-year primary patency rates of below-knee PTFE
grafts to be 59% and 31%, respectively. However, these
results may not reﬂect real-world experience, especially
given the inherent publication bias that exists with these
studies.32 Similarly, PTFE bypass limb salvage rates are com-
parable to or better than those ofmost CVB series,9,13,36 but
direct comparison between PTFE and CVB is difﬁcult
because prosthetic bypasses are unlikely to be used in
patients with poor tibial runoff or overt infection. This point
highlights a potential advantage of CVBs for use within
infected ﬁelds when autogenous vein is unavailable because
prosthetic conduits have yielded inferior results in this
setting and are prone to infection in the presence of infected
ulcers.33 Another important consideration is that patients in
need of a crural bypass often have femoral/popliteal artery
occlusion precluding successful endovascular therapy,
further limiting options in these patients with advanced
disease.37 Moreover, the negative impact of major amputa-
tion in CLI patients has been well documented,38 making
primary amputation also a poor option.
Treatment strategies for CLI have become increasingly
complex owing to the advent of multiple endoluminal,
open, and hybrid revascularization techniques. Accord-
ingly, we concur with Taylor et al,31 who advocate for
Fig 4. A, Freedom from major (above the ankle) amputation in all critical limb ischemia (CLI) patients is demon-
strated on this graph. B, Similar to amputation-free survival (AFS), freedom from major amputation was signiﬁcantly
different (log-rank, P ¼ .01) between rest pain and tissue loss patients. Notably, a signiﬁcant proportion of patients
in the rest pain group underwent concomitant femoral arterial or iliac inﬂow reconstruction at the time of their
cadaveric vein bypass, which likely contributed to these ﬁndings. All displayed time intervals have <10% standard error
of the mean.
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of treatment modality in the CLI patient population. Our
current practice surrounding this unique subset of patients
encompasses a thoughtful strategy that reﬂects a philoso-
phy similar to that of Nehler et al,25 which considers the
patient’s ambulatory status, comorbidities, conduit status,
degree of tissue loss, presence of infection, and complexity
of the required revascularization.In a good-risk, ambulatory patient with minimal pedal
tissue loss, suitable tibial outﬂow, and no autogenous
conduit, an aggressive attempt at revascularization with
alternative conduits is attempted. However, in a nonambu-
latory patient with multiple advanced comorbidities or
extensive tissue loss, primary amputation is typically consid-
ered. The results of this analysis suggest that CVB can be
performed with efﬁcacy similar to reported outcomes of
Fig 5. A, Overall, estimated freedom from major adverse limb events (MALEs) after cadaveric vein bypass for a critical
limb ischemia (CLI) indication was 47% (95% conﬁdence interval [CI], 28-53) and 25% (95% CI, 12-39) at 1 and
3 years, respectively. B, Not surprisingly, primarily owing to signiﬁcant differences in rates of major amputation after
cadaveric vein bypass revascularization, signiﬁcant differences in freedom from MALEs exist between rest pain and
tissue loss patients (P ¼ .004). All displayed time intervals have <10% standard error of the mean.
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are signiﬁcant.12 Bearing this in mind, younger, good-risk
patients with active extremity infection and no usable
autogenous vein may be the optimal group in which to
attempt CVB despite the higher risk of major amputation.
The results of this analysis must be considered within
the limitations of its retrospective, single-center study
design. Small patient numbers and lack of direct, prospec-
tive comparison to alternative strategies, such as prosthetic
bypass or primary amputation, make it difﬁcult to fullydeﬁne the utility of CVB in CLI. However, tremendous
bias in selecting therapy exists for these heterogeneous
groups of patients, which makes any comparison chal-
lenging to interpret. Importantly, no functional outcome
data were provided to better deﬁne success or failure of
CVB outside of limb loss. Further, data regarding return
of rest pain symptoms and time to wound healing in pa-
tients with CVB failure were poorly documented. Finally,
the natural history of medically managed CLI patients pre-
senting after prior failed lower extremity intervention has
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 6 Chang et al 1563been reported previously, but no similar group was avail-
able in this analysis for comparison.
CONCLUSIONS
In CLI patients with no autologous conduit and prior
failed infrainguinal bypass, the clinical outcomes of CVB
are disappointing. CVB performs best in patients with
rest pain, particularly those who can be anticoagulated
postoperatively with warfarin. However, it is also an
acceptable option in patients with tissue loss or graft
infection.
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